Pharmacy & Drug Cost Strategies
Expert articles and analysis related to pharmacy & drug cost strategies.
AI Summary — Last 7 Days
Synthesis: Over the past week, CMS finalized the 2027 Medicare Advantage and Part D payment policies with a notable increase in capitation rates—raising the average expected payment change to 2.48%, a significant upward revision from the proposed 0.09%. This adjustment is accompanied by finalized updates to the 2027 Part D risk adjustment model that further delineate plan payments between MA-PDs and PDPs, directly affecting reimbursement for high-cost therapies and risk-coding dynamics in value-based contracts (Avalere analysis, [Health Tech Nerds summary](https://elinkfef.healthtechnerds.com/ss/c/u001.cQVGOrhtMBOKpKjxZUUQKxMYOGsR8_0G73Q9KdiCCdXd0AQ7bmzMpCiTQnuJiR-aZO2-gXusEzlG3q7uMCR58vfrfrvXQDCX-zjRDCFHrjAPKBttBH83T50sxnOxNulnqIpDy1_eSyafHapXiMsIftHYJofYWUzaHTeEGTSIlNALOMM86u3DUW4VhuGyVe04S1jTCOV1kiC5sEXfuPSw4Q/4pl/NAsqNeAv
Related Articles
change its pharmacy care model
From newsletter: The LI Daily: Ascendiun CEO Paul Markovich wants the industry to back a policy reform movement focused on affordability, tech innovation Ascendiun CEO Paul Markovich wants the indus...
Trends in Manufacturer Coupons for Biologics: Decline in Use Despite Higher Per-Claim Value
Premier Responds to RFI on Potential 340B Rebate Model Pilot Program
Premier raised concerns that a rebate based approach to the 340B drug discount program would undermine the program and create significant risk for hospitals.
Standing up to Rising Prescription Drug Costs Increases Access to Breakthrough Medications
For millions of Americans, accessing the medications they need at prices they can afford has gotten increasingly difficult.
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come
‘Most Favored Nation’ Drug Pricing Is An Idea Whose Time Has Come Health Affairs
In a first, a drugmaker’s lawsuit challenges HRSA’s 340B patient definition
In a new chapter for litigation involving the 340B Drug Pricing Program, a drugmaker is suing the federal government over the definition of patient as it pertains to the program. AbbVie Inc. says the ...
Recent 340B Court Rulings Sustain Blocked WV Law, Demand Decade-Old Federal Policy Be Set Aside
InsideHealthPolicy reports that a federal court ruled in favor of Premier Inc., vacating a decade-old HRSA policy limiting how certain 340B hospitals purchase drugs through group purchasing organizati...
Federal Court Vacates HRSA’s 2013 340B Guidance Prohibiting DSH GPO Use and Replenishment Models
Court vacates 340B policy on hospital drug purchasing: 6 things to know
Becker’s Hospital Review reports that a federal court ruled in favor of Premier Inc., vacating a 2013 HRSA policy restricting 340B hospital drug purchasing after finding the agency failed to adequatel...
Judge vacates HRSA's restriction on 340B hospital 'replenishment models'
Fierce Healthcare covers a federal court ruling vacating HRSA’s 2013 340B purchasing restriction following a lawsuit brought by Premier.